Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

BACKGROUND: Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal antibody to proprotein convertase subtilisin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lipids Health Dis
Hlavní autoři: Teramoto, Tamio, Kondo, Akira, Kiyosue, Arihiro, Harada-Shiba, Mariko, Ishigaki, Yasushi, Tobita, Kimimasa, Kawabata, Yumiko, Ozaki, Asuka, Baccara-Dinet, Marie T., Sata, Masataka
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5474052/
https://ncbi.nlm.nih.gov/pubmed/28623954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12944-017-0513-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky